The development of PD - 1 and PD-L1 has significantly extended the survival time of NSCLC patients, with higher response rates and lower incidence of side effects than anti-cytotoxic T lymphocyte-associated antigen-4 (CTLA - 4) (13, 14). The gene discussed is RPL17; the disease is non-small cell lung carcinoma.